Multicenter Phase II Study of FOLFOX/XELOX and Erbitux as First Line Therapy in Patients with Wild Type KRAS/BRAF Metastatic Colorectal Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Sep 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cetuximab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms FLEET

02 Mar 2018 Pooled analysis of FLEET and FLEET2 studies has been presented in UMIN registry record (Unique ID issued by UMIN:UMIN000031233; Receipt No.: R000035663).
19 Oct 2015 Status changed from active, no longer recruiting to completed, as reported by University Hospital Medical Information Network - Japan record.
09 Jun 2012 Additional lead investigator(Mishima H) identified as reported by University Hospital Medical Information Network - Japan.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com